Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 12/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | CCR2 | P41597 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13147049 | 0.91 | MC4R (0.58) | MC4RTMEM97SIGMAR1CCR2LMNA | |
| SCHEMBL13147070 | 0.83 | MC4R (0.74) | MC4RLMNA | |
| SCHEMBL14223730 | 0.77 | MC4R (0.46) | MC4R | |
| SCHEMBL14339983 | 0.76 | MC4R (0.64) | MC4RLMNA | |
| SCHEMBL3080664 | 0.75 | MC4R (0.58) | MC4RTMEM97SIGMAR1CCR2LMNA | |
| SCHEMBL13147168 | 0.74 | CHRM1 (0.42) | MC4R | |
| SCHEMBL13147146 | 0.74 | MC4R (0.40) | MC4RSIGMAR1 | |
| SCHEMBL3089287 | 0.74 | MC4R (0.82) | MC4R | |
| SCHEMBL13147476 | 0.72 | MC4R (0.62) | MC4RLMNA | |
| SCHEMBL13147461 | 0.72 | MC4R (0.56) | MC4RTMEM97SIGMAR1LMNACCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293498-A1 | Modulators of melanocortin receptor | MC4R, MC1R, MC5R | MC4R 1/4885TMEM97 1697/4885SIGMAR1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.